What a buyer sees
WINZOR PHARMACEUTICALS UK LIMITED
Other manufacturing n.e.c. · Chesham · 07533771
18staff · FY2024
15years trading
48oldest owner on file
£186kcash at bank
Your turnover is on public record
filed£1.6Mfor the year to 2024
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff18
202249 → 182024
Cash at bank£186k
2022£295k → £186k2024
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£87,678below almost all
£90,438£219,207£692,212
Debtor daysdays59in the middle half
205395
Creditor daysdays18
133060
Stock daysdays113above almost all
1144103
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 3
- The newest accounts on file are 30 months oldAnyone looking at the company today is reading a year that has already ended. Whatever has improved since is invisible.
- Stock days run high for your tradeYours is 113 against 44 for the middle of 103 comparable companies. That gap is working capital a buyer has to fund on day one, and it comes off the price.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 1
- A board that has been together ten years or moreContinuity a buyer does not have to take on trust.
What the register says
Owners
- 39since 2016
- 43since 2016
- 48since 2016
Directors
- 48since 2011
- 39since 2012
- 43since 2014
| Year to | Turnover | Staff | Cash |
|---|---|---|---|
| 2024-02-29 | £1.6M | 18 | £186k |
| 2023-02-28 | not filed | 20 | — |
| 2022-02-28 | £1.9M | 49 | £295k |
A rough bracket, and why it is only that
0.4–0.9× sales£630k£1.4M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.